A2ML1 (alpha-2-macroglobulin-like protein 1) is a secreted, monomeric ~180 kDa broad-spectrum protease inhibitor of the alpha-2-macroglobulin family (MEROPS family I39), and the first member of that family found in epidermis. Like other alpha-2-macroglobulins it inhibits by physical entrapment rather than by active-site occlusion: a target protease cleaves an exposed bait region, which triggers a large conformational change that cages the enzyme and exposes an internal isoglutamyl-cysteine thioester, forming a covalent bond between inhibitor and protease. Because the bait region is the main specificity determinant, a single A2ML1 molecule can inhibit endopeptidases from several catalytic classes; recombinant protein inhibits chymotrypsin, papain, thermolysin, subtilisin A and, weakly, elastase, but not trypsin. It is expressed principally in granular-layer keratinocytes of the epidermis and is up-regulated during keratinocyte differentiation, accumulating in keratinosomes (epidermal lamellar bodies) before being secreted into the extracellular space between the granular and cornified layers. In vitro it forms a covalent complex with the desquamation protease kallikrein-7, which is expressed in that same compartment, though the trapping reaction has not been demonstrated in intact skin. Rare A2ML1 variants confer susceptibility to otitis media, and the protein is the p170 autoantigen of paraneoplastic pemphigus.
| GO Term | Evidence | Action | Reason |
|---|---|---|---|
| GO:0004866 endopeptidase inhibitor activity | IEA GO_REF:0000002 | ACCEPT | Summary: InterPro-based electronic assignment of endopeptidase inhibitor activity from the alpha-2-macroglobulin domain architecture. This is correct and is in fact the best molecular-function term available for A2ML1: every protease it has been shown to inhibit (chymotrypsin, papain, thermolysin, subtilisin A, elastase) is an endopeptidase. Independently supported by the enzymology in PMID:16298998, so this IEA is not merely a domain guess. (A QuickGO lookup of the paralog A2M, P01023, shows it carries this same term by IDA as well as IBA/IEA; that is an external check and cannot be verified from within this repository, so it is offered as corroboration rather than as evidence.) Supporting Evidence: PMID:16298998 Recombinant alpha2ML1 displayed inhibitory activity toward chymotrypsin, papain, thermolysin, subtilisin A, and to a lesser extent, elastase but not trypsin. file:human/A2ML1/A2ML1-uniprot.txt Is able to inhibit all four classes of proteinases by a |
| GO:0005576 extracellular region | IEA GO_REF:0000120 | ACCEPT | Summary: Electronic mapping from the UniProt "Secreted" subcellular location, which is itself an experimentally supported assertion (ECO:0000269|PubMed:16298998). Correct core localisation: A2ML1 is secreted into the extracellular space between the uppermost granular layer and the cornified layer of the epidermis. Supporting Evidence: file:human/A2ML1/A2ML1-uniprot.txt SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:16298998}. |
| GO:0070062 extracellular exosome | HDA PMID:19199708 Proteomic analysis of human parotid gland exosomes by multid... | KEEP AS NON CORE | Summary: A2ML1 recovered in a MudPIT proteomic survey of human parotid gland exosomes. A2ML1 is not named in the abstract - it is one of the identified proteins - so the annotation rests on the curator's reading of the dataset. Consistent with a secreted protein, but a co-isolation observation that does not establish dedicated exosomal targeting or an exosome-specific function. Retained as non-core. Supporting Evidence: PMID:19199708 Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT). file:human/A2ML1/A2ML1-uniprot.txt SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:16298998}. |
| GO:0030414 peptidase inhibitor activity | IDA PMID:16298998 A novel protease inhibitor of the alpha2-macroglobulin famil... | MODIFY | Summary: Correct in essence but one level too general. GO:0030414 "peptidase inhibitor activity" is the direct parent of GO:0004866 "endopeptidase inhibitor activity", and the experiment behind this IDA measured inhibition of chymotrypsin, papain, thermolysin, subtilisin A and elastase - all endopeptidases. No exopeptidase inhibition has been reported, and the alpha-2-macroglobulin trapping mechanism inherently targets endopeptidases because it is triggered by internal cleavage of the bait region. The more specific child term should therefore be used. Reason: Term is too shallow for the evidence available; all measured substrates are endopeptidases and the mechanism is endopeptidase-specific. Proposed replacements: endopeptidase inhibitor activity Supporting Evidence: PMID:16298998 Recombinant alpha2ML1 displayed inhibitory activity toward chymotrypsin, papain, thermolysin, subtilisin A, and to a lesser extent, elastase but not trypsin. file:human/A2ML1/A2ML1-uniprot.txt unique 'trapping' mechanism. This protein has a peptide stretch, called |
| GO:0005576 extracellular region | IDA PMID:16298998 A novel protease inhibitor of the alpha2-macroglobulin famil... | ACCEPT | Summary: Direct immunohistochemical demonstration that A2ML1 is secreted into the extracellular space of the epidermis, between the uppermost granular layer and the cornified layer. This is the core cellular-component annotation and the strongest localisation evidence for the gene. Supporting Evidence: PMID:16298998 as a secreted product in the extracellular space between the uppermost granular layer and the cornified layer. |
| GO:0052548 regulation of endopeptidase activity | IDA PMID:16298998 A novel protease inhibitor of the alpha2-macroglobulin famil... | MODIFY | Summary: The essence is right but the term is sign-neutral, which loses the most important fact about this protein. Every measured effect of A2ML1 on a protease is inhibition, and the mechanism - bait-region cleavage followed by conformational entrapment and covalent thioester attachment - can only decrease a target protease's activity against physiological (high molecular weight) substrates. The directional child term GO:0010951 "negative regulation of endopeptidase activity" should be used instead. Reason: Unsigned regulation term for an activity that is exclusively inhibitory; the negative-regulation child is both correct and considerably more informative. Proposed replacements: negative regulation of endopeptidase activity Supporting Evidence: PMID:16298998 Recombinant alpha2ML1 displayed inhibitory activity toward chymotrypsin, papain, thermolysin, subtilisin A, and to a lesser extent, elastase but not trypsin. file:human/A2ML1/A2ML1-uniprot.txt proteinase. The entrapped enzyme remains active against low molecular |
| GO:0002020 protease binding | IPI PMID:16298998 A novel protease inhibitor of the alpha2-macroglobulin famil... | NEW | Summary: Proposed new annotation. Inhibition by an alpha-2-macroglobulin is not active-site occlusion; it proceeds through formation of a stable covalent inhibitor-protease complex. For A2ML1 this was demonstrated directly: incubation with chymotrypsin and with the chymotrypsin-like kallikrein KLK7 showed covalent binding of A2ML1 to both proteases. The covalent adduct is a separately demonstrated binding event rather than an inference from the inhibition assay, and GOA currently records no binding term for A2ML1. KLK7 is a physiologically meaningful partner, being a stratum corneum desquamation protease acting in the very compartment into which A2ML1 is secreted. Reason: Captures the demonstrated protease-trapping interaction, which the inhibitor-activity term alone does not express, and is far more informative than a bare protein-binding term. Supporting Evidence: PMID:16298998 Incubation with chymotrypsin and the chymotrypsin-like kallikrein 7 protease indicated that alpha2ML1 binds covalently to these proteases, a feature shared with other members of the family. file:human/A2ML1/A2ML1-uniprot.txt greatly reduced). Following cleavage in the bait region a thioester file:human/A2ML1/A2ML1-deep-research-affinage.md A2ML1 is a secreted broad-spectrum protease inhibitor of the alpha-2-macroglobulin family expressed in stratified epithelia |
| GO:0097209 epidermal lamellar body | IDA PMID:16298998 A novel protease inhibitor of the alpha2-macroglobulin famil... | NEW | Summary: Proposed new annotation, and the most informative localisation currently missing from A2ML1's GOA record. By immunohistochemistry, A2ML1 was detected within keratinosomes in the granular layer of the epidermis before appearing as a secreted product in the intercellular space. Keratinosomes (also called lamellar granules or Odland bodies) are exactly what GO:0097209 "epidermal lamellar body" denotes - a specialized secretory organelle found in keratinocytes. GOA presently records only the post-secretion extracellular location, leaving the pre-secretory storage compartment unrepresented. Reason: Adds a specific, experimentally demonstrated organelle localisation that explains how A2ML1 reaches the intercellular space of the stratum corneum; complements rather than replaces the extracellular-region annotation. Supporting Evidence: PMID:16298998 By immunohistochemistry, alpha2ML1 was detected within keratinosomes in the granular layer of the epidermis |
Loading supporting content…
Download this section (compressed HTML)Q: Is A2ML1 genuinely a desquamation regulator? Both UniProt and the primary paper only hedge ("May play an important role during desquamation"), and no experiment has yet shown that loss of A2ML1 alters corneodesmosome degradation or stratum corneum cohesion. A demonstration would justify a specific skin-barrier or desquamation biological-process annotation, which the gene currently lacks entirely.
Q: What is the mechanistic link between A2ML1 loss of function and otitis media susceptibility? If unrestrained middle-ear epithelial protease activity is the proximate cause, an epithelial-integrity or defence process annotation might be warranted; if the mechanism is the reported desmoplakin dysregulation, it may instead be a downstream consequence.
Q: Does A2ML1 inhibit threonine endopeptidases? UniProt states the family inhibits "all four classes of proteinases", but the A2ML1-specific enzymology covers only serine, cysteine and metallo endopeptidases. The gap matters for whether the broad endopeptidase-inhibitor term is fully justified for A2ML1 or is partly inherited from A2M.
Q: Are the reported Noonan-syndrome-associated A2ML1 variants pathogenic? A zebrafish study supported a RASopathy-like mechanism, but a later systematic segregation analysis across RASopathy families found the variants inherited from unaffected parents alongside alternative causal aberrations. This should be settled before any developmental-process annotation is contemplated.
Experiment: Assay corneodesmosome degradation and stratum corneum cohesion in reconstructed human epidermis with A2ML1 knocked down or knocked out, measuring KLK5/KLK7 activity in situ with fluorogenic substrates and quantifying desmoglein-1 and corneodesmosin cleavage.
Hypothesis: A2ML1 restrains kallikrein-driven desquamation in the stratum corneum.
Type: cell biology
Experiment: Systematically swap the A2ML1 bait region (residues 695-726) with those of A2M and PZP, and with designed sequences containing or lacking trypsin-cleavable residues, then re-measure the inhibition profile across serine, cysteine, metallo and threonine endopeptidases.
Hypothesis: A2ML1's inhibitory spectrum is set by its bait-region sequence rather than by class-specific active-site recognition.
Type: protein engineering
Experiment: Immunoelectron microscopy of human epidermis co-labelling A2ML1 with established lamellar-body cargo markers, plus live imaging in differentiating keratinocytes, to confirm lamellar-body residence and secretion route and to firm up the proposed GO:0097209 annotation.
Hypothesis: A2ML1 reaches the intercellular space of the stratum corneum via epidermal lamellar bodies.
Type: microscopy
Experiment: Express the reported otitis-media pedigree variants as recombinant protein and measure bait-region cleavage, thioester integrity, covalent complex formation with KLK7 and residual inhibition, distinguishing loss of inhibitory activity from loss of expression or secretion.
Hypothesis: Otitis-media-associated A2ML1 variants act by loss of protease-inhibitory function.
Type: biochemistry
Loading supporting content…
Download this section (compressed HTML)Loading supporting content…
Download this section (compressed HTML)Loading supporting content…
Download this section (compressed HTML)